Amyloid-β Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease
Authors:
- Alvaro Barrera-OcampoABAlvaro Barrera-Ocampo
- Sönke ArltSASönke Arlt
- Jakob MatschkeJMJakob Matschke
- Ursula HartmannUHUrsula Hartmann
- Berta PuigBPBerta Puig
- Isidre FerrerIFIsidre Ferrer
- Petra ZürbigPZPetra Zürbig
- Markus GlatzelMGMarkus Glatzel
- Diego Sepulveda-FallaDSDiego Sepulveda-Falla
- Holger JahnHJHolger Jahn
Open Access
- 30 July 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 75 (9) , 903-916
Abstract
The mechanisms leading to amyloid-β (Aβ) accumulation in sporadic Alzheimer disease (AD) are unknown but both increased production or impaired clearance likely contribute to aggregation. To understand the potential roles of the extracellular matrix proteoglycan Testican-1 in the pathophysiology of AD, we used samples from AD patients and controls and an in vitro approach. Protein expression analysis showed increased levels of Testican-1 in frontal and temporal cortex of AD patients; histological analysis showed that Testican-1 accumulates and co-aggregates with Aβ plaques in the frontal, temporal and entorhinal cortices of AD patients. Proteomic analysis identified 10 fragments of Testican-1 in cerebrospinal fluid (CSF) from AD patients. HEK293T cells expressing human wild type or mutant Aβ precursor protein (APP) were transfected with Testican-1. The co-expression of both proteins modified the sorting of Testican-1 into the endocytic pathway leading to its transient accumulation in Golgi, which seemed to affect APP processing, as indicated by reduced Aβ40 and Aβ42 levels in APP mutant cells. In conclusion, patient data reflect a clearance impairment that may favor Aβ accumulation in AD brains and our in vitro model supports the notion that the interaction between APP and Testican-1 may be a key step in the production and aggregation of Aβ species.Keywords
This publication has 54 references indexed in Scilit:
- Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic BiomarkersPLOS ONE, 2011
- Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cellsExperimental Brain Research, 2011
- Cathepsins S, B and L with aminopeptidases display β-secretase activity associated with the pathogenesis of Alzheimer’s diseaseBiological Chemistry, 2011
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies—A reviewJournal of Neuroscience Research, 2010
- Discovery and validation of urinary biomarkers for prostate cancerProteomics – Clinical Applications, 2008
- Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In VivoNeuron, 2008
- Human proteoglycan testican‐1 inhibits the lysosomal cysteine protease cathepsin LEuropean Journal of Biochemistry, 2003
- Claustrin, an antiadhesive neural keratan sulfate proteoglycan, is structurally related to MAP1BJournal of Neurobiology, 1994
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984